NGM NGM Biopharmaceuticals Inc.

19.73
-0.67  -3%
Previous Close 20.4
Open 20.34
Price To Book 4.22
Market Cap 1,344,439,056
Shares 68,141,868
Volume 278,966
Short Ratio
Av. Daily Volume 335,886
Stock charts supplied by TradingView

NewsSee all news

  1. NGM Bio to Present at Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that

  2. NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (NASDAQ:NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced the

  3. NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results

    -- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- -- Continuing enrollment in Phase 2b ALPINE 2/3

  4. NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

    SOUTH SAN FRANCISCO, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) today announced that, due to public health and safety concerns related to the coronavirus (COVID-19) pandemic,

  5. NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

    --Successfully completed 24-week Phase 2 study (Cohort 4) of aldafermin in non-alcoholic steatohepatitis (NASH) patients, and announced topline results demonstrating positive effect on all key liver histology and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1a/1b trial initiation announced February 11, 2020.
NGM120
Cachexia syndrome
Phase 1 safety & tolerability data 2H 2020.
NGM621
Geographic atrophy
Phase 2 preliminary top-line results from the 24-week cohort (Cohort 4) met primary endpoint - February 24, 2020.
Aldafermin (NGM282)
Non-alcoholic steatohepatitis (NASH)
Phase 2b top-line data due 1H 2021.
NGM282 - ALPINE 2/3
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. NGM Bio to Present at Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that

  2. NGM Bio Appoints Siobhan Nolan Mangini as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (NASDAQ:NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced the

  3. NGM Bio Provides Business Update and Reports First Quarter 2020 Financial Results

    -- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- -- Continuing enrollment in Phase 2b ALPINE 2/3

  4. NGM Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

    SOUTH SAN FRANCISCO, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) today announced that, due to public health and safety concerns related to the coronavirus (COVID-19) pandemic,

  5. NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

    --Successfully completed 24-week Phase 2 study (Cohort 4) of aldafermin in non-alcoholic steatohepatitis (NASH) patients, and announced topline results demonstrating positive effect on all key liver histology and

  6. Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company

    SOUTH SAN FRANCISCO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that,

  7. NGM Bio to Present at Cowen and Company 40th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that

  8. NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo

    --Clinically meaningful response rates of 38% of patients treated with aldafermin having liver fibrosis improvement of ≥1 stage and 24% of patients achieving resolution of NASH at 24 weeks--  --22% of

  9. NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) will host a conference call and live webcast on Monday, February 24, 2020 at 8:30 a.m. ET (5:30 a.m. PT) to

  10. NGM Bio Announces Initiation of Phase 1a/1b Clinical Study of NGM120 for the Potential Treatment of Cancer and Cancer Anorexia/Cachexia Syndrome (CACS)

    --Study to evaluate potential of GDF15/GFRAL pathway inhibition to block tumor-associated weight loss and tumor growth-- --CACS, an uncontrolled wasting syndrome, is a common co-morbidity of cancer and associated with

  11. Horizon Discovery Grants a Multi-Product Use License of its GS knockout CHO K1 Cell Line to NGM Bio

    Cell line to be used to support research and development of biotherapeutics across therapeutic areas Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company" or "the Group"), a global leader in the application

  12. NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  13. NGM Bio to Present at the Stifel 2019 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  14. NGM Reports Business Highlights and Third Quarter 2019 Financial Results

    --Announced positive interim results from ongoing 24-week Phase 2 study evaluating-- --1 mg aldafermin (formerly NGM282) (Cohort 4) in non-alcoholic steatohepatitis (NASH) patients--  --Anticipates full Cohort 4 data,

  15. NGM Bio Announces Appointment of Valerie Pierce as General Counsel

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  16. NGM Bio to Present at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  17. NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

    --Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically significant improvements also observed across key

  18. NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

    --Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically significant improvements also observed across key

  19. NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH

    SOUTH SAN FRANCISCO, Calif., Oct. 06, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 7, 2019 at 8:30 a.m. ET (5:30 a.m. PT) to discuss

  20. NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD's The Liver Meeting®

    SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative